Cargando…
Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma
PURPOSE: Olaratumab is a recombinant human IgG1 monoclonal antibody against PGDFRα. Olaratumab plus doxorubicin improved survivalversus doxorubicin in an open-label, randomised phase 2 soft tissue sarcoma (STS) trial. We characterised the olaratumab exposure–response relationship for progression-fre...
Autores principales: | Jones, Robin L., Mo, Gary, Baldwin, John R., Peterson, Patrick M., Ilaria, Robert L., Conti, Ilaria, Cronier, Damien M., Tap, William D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373189/ https://www.ncbi.nlm.nih.gov/pubmed/30406840 http://dx.doi.org/10.1007/s00280-018-3723-4 |
Ejemplares similares
-
Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer
por: Mo, Gary, et al.
Publicado: (2017) -
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma
por: Villalobos, Victor M., et al.
Publicado: (2019) -
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
por: Gennatas, Spyridon, et al.
Publicado: (2020) -
Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
por: Moroncini, Gianluca, et al.
Publicado: (2018) -
Olaratumab’s failure in soft tissue sarcoma
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)